VolitionRX Ltd (NYSE: VNRX) Starts Presentation at 29th Annual Roth Conference
VolitionRX (NYSE: VNRX) is a clinical-stage life sciences company that focuses on developing blood-based diagnostic tests for detecting and diagnosing cancer and other diseases. The company is involved in the development of 28 epigenetic NuQ blood assays based on its Nucleosomics biomarker discovery platform. It develops two blood assays in the NuQ-X family to detect the presence of cancer by detecting nucleosomes containing specific nucleotides; and three blood tests in the NuQ-V family to detect cancer by detecting nucleosomes containing specific histone variants. VolitionRX also develops 17 blood assays in the NuQ-M family to detect cancer by detecting nucleosomes containing…